Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620976413> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2620976413 endingPage "914" @default.
- W2620976413 startingPage "911" @default.
- W2620976413 abstract "Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patients enrolled in a phase 2, multicenter, open-label study in CLL patients with the 17p deletion. Patients received venetoclax doses within 30 min after the completion of breakfast or the first meal of the day, with no specific recommendations for the fat content in the meal. Blood samples for venetoclax assay were collected during the ramp-up period and on day 1 of weeks 8, 12, 16, 24, and every 12 weeks thereafter. The mean postdose (8 h) plasma venetoclax concentrations increased with increasing weekly venetoclax dose during the ramp-up period to reach 1.89 µg/ml on week 5 day 1 at the 400 mg dose. The mean predose concentration at the 400 mg dose ranged between 0.69 and 0.99 µg/ml across visits between weeks 8 and 120. Repeated-measures analysis detected no statistical significance (P≥0.05) for the mean predose concentrations at any of the times tested from weeks 8 to 24. The study shows that the pharmacokinetic profile of venetoclax in CLL patients with the 17p deletion is comparable to the overall CLL as well as non-Hodgkin’s lymphoma patient populations. Furthermore, no specific recommendation in terms of fat content in the meal is needed for the intake of venetoclax in patients with CLL." @default.
- W2620976413 created "2017-06-09" @default.
- W2620976413 creator A5009328862 @default.
- W2620976413 creator A5053884536 @default.
- W2620976413 creator A5066291807 @default.
- W2620976413 date "2017-09-01" @default.
- W2620976413 modified "2023-10-16" @default.
- W2620976413 title "Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia" @default.
- W2620976413 cites W1987819921 @default.
- W2620976413 cites W2001460917 @default.
- W2620976413 cites W2018562293 @default.
- W2620976413 cites W2094423664 @default.
- W2620976413 cites W2115533945 @default.
- W2620976413 cites W2142741025 @default.
- W2620976413 cites W2149360785 @default.
- W2620976413 cites W2171443164 @default.
- W2620976413 cites W2297120379 @default.
- W2620976413 cites W2318933236 @default.
- W2620976413 cites W2328549977 @default.
- W2620976413 cites W2369297677 @default.
- W2620976413 cites W2401424021 @default.
- W2620976413 cites W2508345698 @default.
- W2620976413 cites W2514200009 @default.
- W2620976413 cites W2517675534 @default.
- W2620976413 cites W2549463667 @default.
- W2620976413 cites W2557713729 @default.
- W2620976413 cites W2565073516 @default.
- W2620976413 cites W2582696216 @default.
- W2620976413 cites W2583145471 @default.
- W2620976413 doi "https://doi.org/10.1097/cad.0000000000000522" @default.
- W2620976413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28562380" @default.
- W2620976413 hasPublicationYear "2017" @default.
- W2620976413 type Work @default.
- W2620976413 sameAs 2620976413 @default.
- W2620976413 citedByCount "24" @default.
- W2620976413 countsByYear W26209764132017 @default.
- W2620976413 countsByYear W26209764132018 @default.
- W2620976413 countsByYear W26209764132019 @default.
- W2620976413 countsByYear W26209764132020 @default.
- W2620976413 countsByYear W26209764132021 @default.
- W2620976413 countsByYear W26209764132022 @default.
- W2620976413 crossrefType "journal-article" @default.
- W2620976413 hasAuthorship W2620976413A5009328862 @default.
- W2620976413 hasAuthorship W2620976413A5053884536 @default.
- W2620976413 hasAuthorship W2620976413A5066291807 @default.
- W2620976413 hasConcept C112705442 @default.
- W2620976413 hasConcept C126322002 @default.
- W2620976413 hasConcept C143998085 @default.
- W2620976413 hasConcept C2777938653 @default.
- W2620976413 hasConcept C2778461978 @default.
- W2620976413 hasConcept C2779338263 @default.
- W2620976413 hasConcept C2779675984 @default.
- W2620976413 hasConcept C71924100 @default.
- W2620976413 hasConcept C90924648 @default.
- W2620976413 hasConcept C98274493 @default.
- W2620976413 hasConceptScore W2620976413C112705442 @default.
- W2620976413 hasConceptScore W2620976413C126322002 @default.
- W2620976413 hasConceptScore W2620976413C143998085 @default.
- W2620976413 hasConceptScore W2620976413C2777938653 @default.
- W2620976413 hasConceptScore W2620976413C2778461978 @default.
- W2620976413 hasConceptScore W2620976413C2779338263 @default.
- W2620976413 hasConceptScore W2620976413C2779675984 @default.
- W2620976413 hasConceptScore W2620976413C71924100 @default.
- W2620976413 hasConceptScore W2620976413C90924648 @default.
- W2620976413 hasConceptScore W2620976413C98274493 @default.
- W2620976413 hasIssue "8" @default.
- W2620976413 hasLocation W26209764131 @default.
- W2620976413 hasLocation W26209764132 @default.
- W2620976413 hasOpenAccess W2620976413 @default.
- W2620976413 hasPrimaryLocation W26209764131 @default.
- W2620976413 hasRelatedWork W1970042929 @default.
- W2620976413 hasRelatedWork W2192121806 @default.
- W2620976413 hasRelatedWork W2358268857 @default.
- W2620976413 hasRelatedWork W2416377892 @default.
- W2620976413 hasRelatedWork W2470301306 @default.
- W2620976413 hasRelatedWork W2590616116 @default.
- W2620976413 hasRelatedWork W2883592788 @default.
- W2620976413 hasRelatedWork W2902590192 @default.
- W2620976413 hasRelatedWork W2904601244 @default.
- W2620976413 hasRelatedWork W2940279791 @default.
- W2620976413 hasVolume "28" @default.
- W2620976413 isParatext "false" @default.
- W2620976413 isRetracted "false" @default.
- W2620976413 magId "2620976413" @default.
- W2620976413 workType "article" @default.